, Columnist
Mylan Is Weighing Options It May Not Have
Its woes have more to do with execution issues and the current drug market than its structure.
Future path is obscured.
Photographer: Jeff Swensen/Getty Images North AmericaThis article is for subscribers only.
Mylan NV had a surprise for investors on Wednesday to go along with the disappointing second-quarter results and slashed full-year guidance it reported: The maker of EpiPens and a host of generic drugs said it’s formed a committee to undertake a strategic review. It believes that its woebegone U.S. operations are causing investors to undervalue its more successful international unit, and every option is on the table.
The problem is, many of Mylan’s woes have to do with its own execution issues and market fundamentals. It’s difficult to imagine what a committee could come up with to fix that.